APA (7th ed.) Citation

Lange, T., Niederwieser, C., Gil, A., Krahl, R., Grünhagen, U. v., Al-Ali, H. K., . . . Niederwieser, D. (2020). No advantage of Imatinib in combination with hydroxyurea over Imatinib monotherapy: A study of the East German Study Group (OSHO) and the German CML study group. Leukemia and lymphoma, 61(12), . https://doi.org/10.1080/10428194.2020.1786556

Chicago Style (17th ed.) Citation

Lange, Thoralf, et al. "No Advantage of Imatinib in Combination with Hydroxyurea over Imatinib Monotherapy: A Study of the East German Study Group (OSHO) and the German CML Study Group." Leukemia and Lymphoma 61, no. 12 (2020). https://doi.org/10.1080/10428194.2020.1786556.

MLA (9th ed.) Citation

Lange, Thoralf, et al. "No Advantage of Imatinib in Combination with Hydroxyurea over Imatinib Monotherapy: A Study of the East German Study Group (OSHO) and the German CML Study Group." Leukemia and Lymphoma, vol. 61, no. 12, 2020, https://doi.org/10.1080/10428194.2020.1786556.